People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| SURGE Therapeutics, Inc. | — | Biotechnology | Series B | $52.6M | $369.2M | 2023 |
Chuck S. Carignan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chuck S. Carignan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Goldberg | 1 | 11 |
| Gary Goldberg | 1 | 5 |
| Kouki S. Harasaki | 1 | 2 |
| Jason S. Coloma | 1 | 1 |
| Antonio S. Gualberto | 1 | 1 |
| Ali S. Farahanchi | 1 | 1 |
| Gary S. Goldberg | 1 | 1 |
| Michael S. Goldberg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.